BioXcel Therapeutics amends ARx supply agreement to reduce minimum annual payments over next three years

BioXcel Therapeutics, Inc.

Amendment reduces specified minimum annual payment due to ARx for next three years starting 2024.
Thereafter, minimum annual payments only required if FDA approves sNDA or NDA for listed indications.
No specific financial terms or amounts disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.